Skip to content
OpenCapital
Get started

West Pharmaceutical Services WST Cash & Equivalents

Cash & Equivalents at other companies

Becton, Dickinson and Company logo
Becton, Dickinson and CompanyBDX
$1.02B+49.0%
AptarGroup logo
AptarGroupATR
$224.95M+78.8%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$312.01M+76.9%
AVT
AvantorAVTR
$282.2M-11.4%
Dow logo
DowDOW
$4.24B+172%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$752M-57.1%

Other financials

Income statement

See full
Revenue$844.9M+21.0%
Gross profit$296.4M+27.8%
Operating income$177.1M+65.5%
Net income$138.8M+54.6%
EPS (diluted)$1.92+56.1%

Balance sheet

See full
Total debt$321.0M+4.4%
Total equity$3.0B+11.5%
Total assets$4.1B+13.6%

Cash flow

See full
Operating cash flow$89.9M-30.5%
CapEx$42.7M-40.1%
Free cash flow$47.2M-18.8%

Valuation

See full
Market cap$25.36B+64.2%
Enterprise value$25.16B+65.1%
P/E46.7×+15.1×
P/S7.9×+2.7×

Profitability

See full
Gross margin36.3%+1.7pp
Operating margin20.3%+1.2pp
Net margin16.8%+0.7pp
FCF margin14.2%+3.6pp

Returns & leverage

See full
Return on equity19.1%+1.7pp
Debt / equity0.1×0.0×
Current ratio2.7×-0.1×

Where this comes from

Reported directly by West Pharmaceutical Services in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: West Pharmaceutical Services’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about West Pharmaceutical Services's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is West Pharmaceutical Services's cash & equivalents?
West Pharmaceutical Services (WST) reported cash & equivalents of $521.4M in Q1 2026.
How has West Pharmaceutical Services's cash & equivalents changed year-over-year?
West Pharmaceutical Services's cash & equivalents increased by 29.0% year-over-year, from $404.2M to $521.4M.
What is the long-term trend for West Pharmaceutical Services's cash & equivalents?
Over 5 years (2020 to 2025), West Pharmaceutical Services's cash & equivalents has grown at a 5.2% compound annual growth rate (CAGR), from $615.5M to $791.3M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.